Learn more
Order today
Introduced in the U.S. House of Representatives on March 24, 2022, the Equitable Community Access to Pharmacist Services Act, H.R. 7213, would authorize pharmacists to provide care and receive reimbursement for pandemic-related services for our nation’s seniors.
We’re excited to announce the launch of the new APhA Learning Library! This new platform will make it easier than ever for you to get the education you need. Read about some key highlights of our new system.
APhA is committed to facilitating meaningful dialogue between pharmacy management, pharmacy team members, and other stakeholders that result in improved workplaces, well-being, and ability to meet ethical obligations to patient safety.
June 2022 ACIP Immunization Update
Battle Against SDOH & Disparities in Pain Mgmt, Part 1
JFPS 2022
Tools and resources to support your practice
Access Now
APhA’s monthly Pulse on Practice and Policy Open Forum Series creates a platform where all of pharmacy can come together to share perspectives and be informed of key practices and policies impacting the profession.
An APhA member-only resource for pharmacists, pharmacy residents, student pharmacists, pharmacy technicians, and interprofessional health care team members involved in providing transitions of care (TOC) services.
An outline of the key steps to implementing monoclonal antibody therapy administration services in community settings.
View CEO Blog
A letter from Interim CEO Ilisa Bernstein, PharmD, JD, FAPhA, to Dr. Robert Califf, Commissioner of the Food and Drug Administration (FDA), on the importance of pharmacists being allowed to prescribe oral COVID-19 treatments.
View all press releases
Today, after months of effort by APhA and other stakeholders, FDA has updated the EUA for the COVID-19 oral antiviral, Paxlovid, to permit pharmacists to order and prescribe Paxlovid under certain conditions.
View all news
CDC Director Rochelle P. Walensky, MD, MPH, adopted the Advisory Committee on Immunization Practices’ (ACIP) recommendation to preferentially recommend the use of specific influenza vaccines for adults aged 65 years and older, including higher-dose and adjuvanted influenza vaccines.
On Monday, FDA issued a proposed rule aimed at expanding the range of marketed nonprescription drugs available to consumers. The Nonprescription Drug Product with an Additional Condition for Nonprescription Use rule seeks to empower consumers to self-treat certain common conditions and improve public health.